Chemical kinetic mechanistic models to investigate cancer biology and impact cancer medicine

Physical Biology

Volumn 10, Issue 2, 2013, Pages

  Stites, Edward C ^a,b  

^a TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BIOLOGICAL MODEL; COMPUTER SIMULATION; GENETICS; HUMAN; METABOLISM; MUTATION; NEOPLASM; SIGNAL TRANSDUCTION; SYSTEMS BIOLOGY;

COMPUTER SIMULATION; HUMANS; MODELS, BIOLOGICAL; MUTATION; NEOPLASMS; SIGNAL TRANSDUCTION; SYSTEMS BIOLOGY;

EID: 84876241551     PISSN: 14783967     EISSN: 14783975     Source Type: Journal    
DOI: 10.1088/1478-3975/10/2/026004     Document Type: Article

References (60)

1. Evan G I and Vousden K H 2001 Proliferation, cell cycle and apoptosis in cancer Nature 411 342-48
2. Yarden Y and Sliwkowski M X 2001 Untangling the ErbB signalling network Nature Rev. Mol. Cell Biol. 2 127-37
3. Lim W A and Pawson T 2010 Phosphotyrosine signaling: evolving a new cellular communication system Cell 142 661-7
4. Roskoski R Jr 2012 MEK1/2 dual-specificity protein kinases: structure and regulation Biochem. Biophys. Res. Commun. 417 5-10
5. Chen R H, Sarnecki C and Blenis J 1992 Nuclear localization and regulation of erk- and rsk-encoded protein kinases Mol. Cell Biol. 12 915-27 (available at http://mcb.asm.org/content/12/3/915.long)
6. Chambard J C, Lefloch R, Pouyssegur J and Lenormand P 2007 ERK implication in cell cycle regulation Biochim. Biophys. Acta 1773 1299-310
7. Stratton M R, Campbell P J and Futreal P A 2009 The cancer genome Nature 458 719-24
8. Greaves M and Maley C C 2012 Clonal evolution in cancer Nature 481 306-13
9. McLendon R et al 2008 Comprehensive genomic characterization defines human glioblastoma genes and core pathways Nature 455 1061-8
10. Ding L et al 2008 Somatic mutations affect key pathways in lung adenocarcinoma Nature 455 1069-75
11. Wang Z, Longo P A, Tarrant M K, Kim K, Head S, Leahy D J and Cole P A 2011 Mechanistic insights into the activation of oncogenic forms of EGF receptor Nature Struct. Mol. Biol. 18 1388-93
12. Hanahan D and Weinberg R A 2000 The hallmarks of cancer Cell 100 57-70
13. Jones S et al 2008 Core signaling pathways in human pancreatic cancers revealed by global genomic analyses Science 321 1801-6
14. Davies H et al 2002 Mutations of the BRAF gene in human cancer Nature 417 949-54
15. Sawyers C 2004 Targeted cancer therapy Nature 432 294-7
16. Sharma S V and Settleman J 2007 Oncogene addiction: setting the stage for molecularly targeted cancer therapy Genes Dev. 21 3214-31
17. Ciardiello F and Tortora G 2008 EGFR antagonists in cancer treatment New Engl. J. Med. 358 1160-74
18. Lynch T J et al 2004 Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib New Engl. J. Med. 350 2129-39
19. Pao W et al 2004 EGF receptor gene mutations are common in lung cancers from 'never smokers' and are associated with sensitivity of tumors to gefitinib and erlotinib Proc. Natl Acad. Sci. USA 101 13306-11
20. Pao W, Miller V A, Politi K A, Riely G J, Somwar R, Zakowski M F, Kris M G and Varmus H 2005 Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain PLoS Med. 2 e73
21. Linardou H, Dahabreh I J, Kanaloupiti D, Siannis F, Bafaloukos D, Kosmidis P, Papadimitriou C A and Murray S 2008 Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer Lancet Oncol. 9 962-72
22. Moore M J et al 2007 Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group J. Clin. Oncol. 25 1960-6
23. Engelman J A et al 2007 MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling Science 316 1039-43
24. Courtois-Cox S, Genther Williams S M, Reczek E E, Johnson B W, McGillicuddy L T, Johannessen C M, Hollstein P E, MacCollin M and Cichowski K 2006 A negative feedback signaling network underlies oncogene-induced senescence Cancer Cells 10 459-72
25. Prahallad A, Sun C, Huang S, Di Nicolantonio F, Salazar R, Zecchin D, Beijersbergen R L, Bardelli A and Bernards R 2012 Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR Nature 483 100-3
26. Poulikakos P I, Zhang C, Bollag G, Shokat K M and Rosen N 2010 RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF Nature 464 427-30
27. Hatzivassiliou G et al 2010 RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth Nature 464 431-5
28. Heidorn S J et al 2010 Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF Cell 140 209-21
29. Downward J 2003 Targeting RAS signalling pathways in cancer therapy Nature Rev. Cancer 3 11-22
30. Ideker T and Lauffenburger D 2003 Building with a scaffold: emerging strategies for high- to low-level cellular modeling Trends Biotechnol. 21 255-62
31. Arkin A P and Schaffer D V 2011 Network news: innovations in 21st century systems biology Cell 144 844-9
32. Aldridge B B, Burke J M, Lauffenburger D A and Sorger P K 2006 Physicochemical modelling of cell signalling pathways Nature Cell Biol. 8 1195-203
33. Bachmann J, Raue A, Schilling M, Becker V, Timmer J and Klingmuller U 2012 Predictive mathematical models of cancer signalling pathways J. Intern. Med. 271 155-65
34. Bhalla U S, Ram P T and Iyengar R 2002 MAP kinase phosphatase as a locus of flexibility in a mitogen-activated protein kinase signaling network Science 297 1018-23
35. Schoeberl B, Eichler-Jonsson C, Gilles E D and Muller G 2002 Computational modeling of the dynamics of the MAP kinase cascade activated by surface and internalized EGF receptors Nature Biotechnol. 20 370-5
36. Hoffmann A, Levchenko A, Scott M L and Baltimore D 2002 The IkappaB-NF-kappaB signaling module: temporal control and selective gene activation Science 298 1241-5
37. Spencer S L, Gaudet S, Albeck J G, Burke J M and Sorger P K 2009 Non-genetic origins of cell-to-cell variability in TRAIL-induced apoptosis Nature 459 428-32
38. Das J, Ho M, Zikherman J, Govern C, Yang M, Weiss A, Chakraborty A K and Roose J P 2009 Digital signaling and hysteresis characterize ras activation in lymphoid cells Cell 136 337-51
39. Stites E C, Trampont P C, Ma Z and Ravichandran K S 2007 Network analysis of oncogenic Ras activation in cancer Science 318 463-7
40. Sorger P K 2005 A reductionist's systems biology: opinion Curr. Opin. Cell Biol. 17 9-11
41. Stites E C and Ravichandran K S 2009 A systems perspective of ras signaling in cancer Clin. Cancer Res. 15 1510-3
42. Kleiman L B, Maiwald T, Conzelmann H, Lauffenburger D A and Sorger P K 2011 Rapid phospho-turnover by receptor tyrosine kinases impacts downstream signaling and drug binding Mol. Cell. 43 723-37
43. Orton R J, Adriaens M E, Gormand A, Sturm O E, Kolch W and Gilbert D R 2009 Computational modelling of cancerous mutations in the EGFR/ERK signalling pathway BMC Syst. Biol. 3 100
44. Chandarlapaty S 2012 Negative feedback and adaptive resistance to the targeted therapy of cancer Cancer Discovery 2 311-9
45. Fritsche-Guenther R, Witzel F, Sieber A, Herr R, Schmidt N, Braun S, Brummer T, Sers C and Bluthgen N 2011 Strong negative feedback from Erk to Raf confers robustness to MAPK signalling Mol. Syst. Biol. 7 489
46. Mangan S and Alon U 2003 Structure and function of the feed-forward loop network motif Proc. Natl Acad. Sci. USA 100 11980-5
47. Iyengar R, Zhao S, Chung S W, Mager D E and Gallo J M 2012 Merging systems biology with pharmacodynamics Sci. Transl. Med. 4 1-6
48. Hornberg J J, Bruggeman F J, Westerhoff H V and Lankelma J 2006 Cancer: a systems biology disease Biosystems 83 81-90
49. Orton R J, Sturm O E, Vyshemirsky V, Calder M, Gilbert D R and Kolch W 2005 Computational modelling of the receptor-tyrosine-kinase-activated MAPK pathway Biochem. J. 392 249-61
50. Bajikar S S and Janes K A 2012 Multiscale models of cell signaling Ann. Biomed. Eng. 40 2319-27
51. Hlavacek W S, Faeder J R, Blinov M L, Posner R G, Hucka M and Fontana W 2006 Rules for modeling signal-transduction systems Sci. STKE re6 pp 1-18 (available at http://stke.sciencemag.org/cgi/content/abstract/sigtrans;2006/344/ re6)
52. Blinov M L, Faeder J R, Goldstein B and Hlavacek W S 2004 BioNetGen: software for rule-based modeling of signal transduction based on the interactions of molecular domains Bioinformatics 20 3289-91
53. Colvin J, Monine M I, Gutenkunst R N, Hlavacek W S, Von Hoff D D and Posner R G 2010 RuleMonkey: software for stochastic simulation of rule-based models BMC Bioinformatics 11 404
54. Sneddon M W, Faeder J R and Emonet T 2011 Efficient modeling, simulation and coarse-graining of biological complexity with NFsim Nature Methods 8 177-83
55. Woodcock J, Griffin J P and Behrman R E 2011 Development of novel combination therapies New Engl. J. Med. 364 985-7
56. Chin L, Andersen J N and Futreal P A 2011 Cancer genomics: from discovery science to personalized medicine Nature Med. 17 297-303
57. Tian Q, Price N D and Hood L 2012 Systems cancer medicine: towards realization of predictive, preventive, personalized and participatory (P4) medicine J. Intern. Med. 271 111-21
58. Tran B et al 2012 Cancer genomics: technology, discovery, and translation J. Clin. Oncol. 30 647-60
59. Roychowdhury S et al 2011 Personalized oncology through integrative high-throughput sequencing: a pilot study Sci. Transl. Med. 3 1-10
60. Von Hoff D D et al 2010 Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers J. Clin. Oncol. 28 4877-83